IRIS
BIANCO, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.961
EU - Europa 5.544
NA - Nord America 4.724
SA - Sud America 781
AF - Africa 183
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 5
Totale 17.211
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.535
SG - Singapore 3.221
RU - Federazione Russa 2.513
CN - Cina 1.394
IT - Italia 1.375
BR - Brasile 645
HK - Hong Kong 480
VN - Vietnam 446
DE - Germania 403
UA - Ucraina 233
FI - Finlandia 221
NL - Olanda 217
IE - Irlanda 141
IN - India 130
CA - Canada 128
GB - Regno Unito 119
FR - Francia 95
CI - Costa d'Avorio 79
SE - Svezia 74
AR - Argentina 61
KR - Corea 53
PL - Polonia 43
ZA - Sudafrica 42
MX - Messico 41
PK - Pakistan 33
BD - Bangladesh 32
ES - Italia 27
JP - Giappone 26
ID - Indonesia 24
TR - Turchia 22
EC - Ecuador 21
BE - Belgio 20
IQ - Iraq 15
AT - Austria 14
MA - Marocco 14
VE - Venezuela 12
EG - Egitto 11
UZ - Uzbekistan 11
CO - Colombia 10
IL - Israele 9
MY - Malesia 9
PY - Paraguay 9
TN - Tunisia 9
CL - Cile 8
LT - Lituania 8
AU - Australia 7
IR - Iran 7
PE - Perù 7
SA - Arabia Saudita 7
AZ - Azerbaigian 6
JO - Giordania 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
BO - Bolivia 4
HN - Honduras 4
KE - Kenya 4
NP - Nepal 4
SK - Slovacchia (Repubblica Slovacca) 4
AO - Angola 3
CH - Svizzera 3
DK - Danimarca 3
ET - Etiopia 3
GR - Grecia 3
KZ - Kazakistan 3
NZ - Nuova Zelanda 3
RS - Serbia 3
SI - Slovenia 3
BA - Bosnia-Erzegovina 2
BS - Bahamas 2
CG - Congo 2
CR - Costa Rica 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
KG - Kirghizistan 2
KH - Cambogia 2
LK - Sri Lanka 2
MK - Macedonia 2
PA - Panama 2
PT - Portogallo 2
UY - Uruguay 2
XK - ???statistics.table.value.countryCode.XK??? 2
YT - Mayotte 2
AD - Andorra 1
AP - ???statistics.table.value.countryCode.AP??? 1
BB - Barbados 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
BZ - Belize 1
CW - ???statistics.table.value.countryCode.CW??? 1
EU - Europa 1
GH - Ghana 1
GI - Gibilterra 1
GM - Gambi 1
HR - Croazia 1
HT - Haiti 1
Totale 17.188
Salva come PNG Salva come JPEG
Città #
Singapore 1.470
Moscow 640
Chandler 524
Hong Kong 479
Beijing 449
Ashburn 406
Naples 336
Hefei 311
Jacksonville 235
Santa Clara 229
Napoli 189
Amsterdam 187
Dallas 176
Ho Chi Minh City 163
Munich 160
Millbury 156
Los Angeles 132
Princeton 116
Hanoi 91
Boston 87
New York 77
Buffalo 75
Nanjing 74
São Paulo 71
Redondo Beach 64
The Dalles 61
Turku 61
Wilmington 60
Ottawa 56
Rome 54
Woodbridge 54
Seoul 52
Des Moines 45
Kochi 45
San Jose 40
Helsinki 37
Seattle 37
Houston 36
Nanchang 35
Warsaw 34
Orem 30
Brooklyn 28
Dong Ket 28
Montreal 28
Pune 28
London 27
Falkenstein 26
Milan 26
Chicago 25
Hebei 25
Caserta 24
Frankfurt am Main 24
Stockholm 24
Tokyo 24
Boardman 23
Hicksville 23
Shenyang 23
Mexico City 22
Toronto 22
Denver 21
Lawrence 20
Nuremberg 20
Tianjin 20
Norwalk 19
Ann Arbor 18
Biên Hòa 18
Changsha 18
Haiphong 18
Phoenix 18
Atlanta 16
Da Nang 16
Johannesburg 16
Rio de Janeiro 16
Jiaxing 15
Salt Lake City 15
Belo Horizonte 14
Brussels 14
Kronberg 14
Porto Alegre 14
Redwood City 14
Islamabad 13
Chennai 12
Formia 12
Guangzhou 12
Lahore 12
Ninh Bình 12
Poplar 12
San Mateo 12
Shanghai 12
Manchester 10
Pozzuoli 10
Salvador 10
San Francisco 10
Tashkent 10
Casablanca 9
Casoria 9
Dublin 9
Turin 9
Vienna 9
Washington 9
Totale 8.651
Salva come PNG Salva come JPEG
Nome #
null 223
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 177
The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity 163
Development of 1,2,3-Triazole-Based Sphingosine Kinase Inhibitors and Their Evaluation as Antiproliferative Agents 155
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 146
Epigenetic silencing of THY1 tracks the acquisition of the Notch1-EGFR signaling in a xenograft model of CD44+/CD24low/CD90+ myoepithelial cells 144
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 137
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 136
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 134
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 133
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 129
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 129
AXL is an oncotarget in human colorectal cancer 127
Mechanisms of resistance to mTOR inhibitors 127
Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy 126
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 124
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 123
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 122
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 122
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 122
Addition of erlotinib to fluoropyrimidine-oxaliplatin-basedchemotherapy with or without bevacizumab: Two sequential phase I trials 121
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 121
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 121
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 120
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 120
Evaluation of exercise capacity by means of cardiopulmonary exercise testing (CPET) in older adult cancer patients undergoing antineoplastic treatments 119
Increased anaerobic metabolism is a distinctive signature in a colorectal cancer cellular model of resistance to anti-epidermal growth factor receptor antibody 119
Toll-like receptor 9 agonist IMO cooperates with everolimus in renal cell carcinoma by interfering with tumour growth and angiogenesis. 118
NTRK Fusions, from the Diagnostic Algorithm to Innovative Treatment in the Era of Precision Medicine 117
Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling. 116
Paraneoplastic sensitive neuropathy associated with anti-hu antibodies in a neuroendocrine tumor of duodenum: a case report. 116
Studio dei meccanismi autocrini e paracrini di attivazione di Hedgehog in modelli tumorali umani. 116
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. 115
Antitumor activity of combined treatment of human cancer cells with ionizing radiations and anti-epidermal growth factor receptor monoclonal antibody C225 plus type I protein kinase A antisense oligonucleotide. 115
Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide. 115
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer 115
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 115
The Impact of Translational Research in Breast Cancer Care: Can We Improve the Therapeutic Scenario? 114
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 113
Powerful anti-tumor and anti-angiogenic activity of a new anti-vascular endothelial growth factor receptor 1 peptide in colorectal cancer models 113
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 113
Prevention of cardiovascular complications in elderly cancer patients 113
Epidermal growth factor receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. 111
Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models 110
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 109
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 109
Mechanisms of lapatinib resistance in HER2-driven breast cancer 109
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents 109
Inhibition of growth factors production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. 108
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 108
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 107
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 107
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 106
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. 106
Enzastaurin inhibits tumors sensitive and resistant to anti-EGFR drugs 106
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 106
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 106
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 105
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 103
Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: tolerability, and prognostic factors. 103
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. 103
Predictors of outcomes in patients with EGFR-mutated non-small cell lung cancer receiving EGFR tyrosine kinase inhibitors: A systematic review and meta-analysis 103
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 102
COMBINED TARGETING OF EGFR AND MDM2 BY GEFITINIB AND ANTISENSE MDM2 COOPERATIVELY INHIBIT HORMONE-INDEPENDENT PROSTATE CANCER. 102
Phase I-II study of xelox and bevacizumab plus erlotinib in sequential combination (XELOX-TARAV) in first line colorectal cancer: run in part 102
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 101
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 101
Combination of biological therapies in non-small cell lung cancer. 101
High-rsolution melting analysis (HRMA) for KRAS mutatiinal study in patients with metastatic colorectal cancer (mCRC pts) 101
From biology to therapy: Improvements of therapeutic options in Lung cancer 101
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 101
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 100
KRAS mutations in advanced non-small cell lung cancer: From biology to novel therapeutic strategies 100
RET Inhibitors in Non-Small-Cell Lung Cancer 99
Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells 99
Approaches for targeting cancer stem cells drug resistance 99
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 98
Antiangiogenic and antitumor activity of anti-EGFR C225 monoclonal antibody in combination with Vascular Endothelial Growth Factor antisense oligonucleotide in human GEO colon cancer cells. 98
A phase II study of beweekly oxaliplatin plus infusional 5fluorouracil and folinic acid (FOLFOX4) as first-line treatment of advenced gastric cancer patients 98
How can we manage the cardiac toxicity of immune checkpoint inhibitors? 98
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. 97
Evaluation of HER2-specific peptide ligand for its employment as radiolabeled imaging probe 97
Association of FGFR1 with ERαmaintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer 96
MONOCLONAL ANTIBODIES TARGETING THE EPIDERMAL GROWTH FACTOR RECEPTOR. 95
Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease. 95
Effect on quality of life of cisplatin added to single-agent chemotherapy as first-line treatment for elderly patients with advanced non-small cell lung cancer: Joint analysis of MILES-3 and MILES-4 randomised phase 3 trials 95
Preliminary analysis of chemotheraphy-induced cardiotoxicity in breast cancer patients trated with Amifostine. 94
A Novel Toll-Like Receptor 9 Agonist Cooperates with Trastuzumab in Trastuzumab-Resistant Breast Tumors through Multiple Mechanisms of Action 94
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 93
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial 93
Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi-Center Real-Life Study 93
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. 93
Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an EGFR-selective tyrosine kinase inhibitor. 93
Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A. 93
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 92
Core curriculum. Oncologia clinica 92
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 91
Checkpoint based immunotherapy in non-small cell lung cancer: a real-world retrospective study 91
Bevacizumab related arterial hypertension as a predictive marker in metastatic Colorectal Cancer (mCRC) patients 91
SPHINGOSINE KINASE 1 (SPHK1) CONTRIBUTES TO RESISTANCE TO EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITORS IN COLORECTAL CANCER MODELS 91
Totale 11.168
Salva come PNG Salva come JPEG
Categoria #
all - tutte 56.007
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.007
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021321 0 0 0 0 0 0 69 11 89 29 79 44
2021/2022879 16 1 11 25 12 25 11 29 156 73 206 314
2022/20231.367 152 110 48 102 146 163 8 129 207 197 64 41
2023/20241.000 35 140 138 100 45 106 25 118 20 21 194 58
2024/20255.494 236 258 15 99 165 279 575 372 336 600 2.117 442
2025/20266.558 1.179 794 1.238 976 1.837 498 36 0 0 0 0 0
Totale 17.514